Clinical Trial Update: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update for crizotinib in ALK-positive stage IB-IIIA non-small cell lung cancer as part of the ALCHEMIST program. The trial is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Xalkori (crizotinib)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: ALK Gene Rearrangement, ALK Gene Translocation | Phase 3 | Status: ACTIVE_NOT_RECRUITING